SCHOTT Pharma AG & Co. KGaA (1SXP.DE) Thursday said that its fourth-quarter profit declined from last year. While revenues rose from the prior year, the company also provided outlook for fiscal 2026. The company also declared a dividend for fiscal 2025.
The pharmaceutical glass packaging company reported fourth quarter profit of 33 million euros, down from 34 million euros in the year-ago period. On a per share basis, earnings remained constant at 0.22 euros, in comparison to the same period last year.
During the three-month period, revenues rose to 247.0 million euros from 237.1 million euros in the previous-year quarter. EBITDA for the period climbed to 67 million euros from 66 million euros in the corresponding quarter a year ago.
Looking ahead, the company said that it projects revenue growth of between 2 percent and 5 percent, on a constant currency basis and an EBITDA margin of around 27 percent.
Additionally, SCHOTT Pharma has also updated its mid-term outlook for 2027-2029, forecasting a revenue CAGR of 6 percent to 8 percent. The company also expects its EBITDA margin to touch 30 percent over the given period.
The company said that its Management Board and Supervisory Board will propose a dividend of 0.18 euros per share for fiscal 2025 at the Annual General Meeting scheduled for February 3, 2026.
On the XETRA Exchange, the stock ended Wednesday's trading at 15.80 euros, up 1.4 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.